Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Jeanne Fabre
Temporary status for medical cannabis adopted during the 2024 PLFSS first reading (France)
On 17 November 2023, the French Social Security Financing Bill for 2024 was adopted on first reading by the French Senate. In its current version, the Bill includes Article 36bis (formerly amendment No 3298 introduced by the French government), which provides for the creation of a temporary status for cannabis-based medicines.
Submission of the report on health products (France)
A mission commissioned by the French Prime Minister, Elisabeth Borne, has issued its report on the financing and regulation of health products containing multiple recommendations with a view to improve access to medicines, tackle shortages and relocate certain activities for strategic healthcare products.
5 Tips for Navigating PIPEs in the European Life Sciences Sector | JD Supra
The challenging funding environment will likely prompt small- and mid-cap listed life sciences companies to seek financing through private investments in public equity. Small- and mid-cap life sciences companies typically draw upon two major fundraising sources: licensing and collaboration agreements (which have the potential to provide funding without dilution) and equity injections.
EU MDR Transitional Provisions Officially Extended | JD Supra
The revised provisions provide medical device and in-vitro diagnostics manufacturers with additional time to bring their product into compliance with the new EU Regulations, subject to a number of conditions. On March 20, 2023, Regulation (EU) no 2023/607 was published in the Official Journal of the European Union, following speedy adoption by the European Parliament and Council.
Life Sciences Law Review - 11th Edition, France Chapter | JD Supra
The eleventh edition of The Life Sciences Law Review covers a total of 24 jurisdictions, providing an overview of legal requirements of interest to pharmaceutical, biotechnology and medical device companies. The chapters are arranged so as to describe requirements throughout the life cycle of a regulated product, from discovery to clinical trials, the marketing authorisation process and post-approval controls.
In review: the life sciences regulatory regime in France
All questions Introduction France is generally known for its high quality and also highly regulated healthcare system. As an EU Member State, France has implemented the EU medicines and medical devices regimes. This chapter should therefore be read in conjunction with the EU chapter and focuses on the specifics of the French regulatory regime.
France: FCA Increases Scrutiny Over the Sector
France is a key jurisdiction to consider when discussing the life sciences sector. This chapter presents the main recent antitrust developments in this sector in France by examining recent regulatory developments and covid-19 measures, the French Competition Authority’s (FCA) enforcement in recent mergers and antitrust cases and the likely short-term outlook for the sector.
New Regulation on Health Technology Assessment Seeks to Facilitate EU-Level Joint Clinical Assessments From 2025 | JD Supra
The regulation aims to harmonise clinical and scientific aspects of HTA to make innovative health technologies more widely available in the EU. Health technology assessment (HTA) is a multidisciplinary evidence-based process that allows authorities to determine the relative effectiveness of new or existing health technologies (e.g., medicines and medical devices), focusing on the added value of a health technology.
Life Sciences Law Review - 10th Edition, France Chapter | JD Supra
France is generally known for its high quality and also highly regulated healthcare system. As an EU Member State, France has implemented the EU medicines and medical devices regimes. This chapter should therefore be read in conjunction with the EU chapter and will focus on the specifics of the French regulatory regime. France has codified the essential rules on medicines and medical devices in the French Public Health Code, which encompasses both statutory and regulatory provisions.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Jeanne
Contact Jeanne, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack